Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MENS

Jyong Biotech Ltd

Dec 30 • 04:00PM ET

4.22

+1.44 51.80 %

Healthcare • Biotechnology • Taiwan • NASD

Today, 12:01 PMTechnical rebound and short covering after lock-up expiry fueled 34.53% intraday gain.

Held by: IBB ONEQ IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.04	Insider Own	62.20%	Shs Outstand	74.23M	Perf Week	-11.72%
Market Cap	320.84M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	28.06M	Perf Month	-84.49%
Enterprise Value	338.88M	PEG	-	EPS next Q	-	Inst Own	0.14%	Short Float	0.90%	Perf Quarter	-89.28%
Income	-3.02M	P/S	-	EPS this Y	-	Inst Trans	8.26%	Short Ratio	0.31	Perf Half Y	-50.24%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.25M	Perf YTD	-58.26%
Book/sh	-0.49	P/C	3208.41	EPS next 5Y	-	ROE	-	52W High	67.00 -93.70%	Perf Year	-
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	11.49% -	ROIC	-	52W Low	2.60 62.25%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	31.44% 50.92%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	3.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	23.36	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.02	EPS Q/Q	-	SMA20	-73.80%	Beta	-	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-86.41%	Rel Volume	4.54	Prev Close	2.78
Employees	29	LT Debt/Eq	-	Earnings	-	SMA200	-87.62%	Avg Volume	815.77K	Price	4.22
IPO	Jun 17, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	3,700,024	Change	51.80%

Dec-19-25 09:00AM	Jyong Biotech Responds to Share Price and Volume Movement (GlobeNewswire)
Dec-04-25 08:30AM	Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS-2 Market Entry (GlobeNewswire)
Nov-24-25 08:30AM	Jyong Biotech Ltd. Signs Non-Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In-Licensing of Plant-Derived MCS Drugs (GlobeNewswire) +15.16%
Nov-21-25 08:45AM	Jyong Biotech completes primary endpoint analysis for Phase II trial of MCS-8 (TipRanks) -6.28%
Nov-20-25 08:30AM	Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes (GlobeNewswire) +12.44%
08:30AM	Loading…
Sep-29-25 08:30AM	Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards (GlobeNewswire) -16.30%
Sep-18-25 08:30AM	Jyong Biotech Chairwoman and CEO Set to Attend as Speaker at 2025 Global Business Forum in Taipei (GlobeNewswire)
Sep-16-25 08:18AM	Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS-8 for Prostate Cancer Prevention (GlobeNewswire) +5.02%
Sep-03-25 07:30AM	These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025 (Motley Fool)
Aug-22-25 09:00AM	Jyong Biotech Ltd. Participated in the 22nd Urological Association of Asia Congress to Display the Clinical Data for its Phase III Studies of BOTRESO and Phase II Study of MCS-8 (PCP) (GlobeNewswire) +6.58%
Jul-22-25 10:40AM	Jyong Biotech Ltd. Rings Nasdaq Bell and Participates at the BIO 2025 International Convention (GlobeNewswire) -8.55%
Jun-18-25 05:20PM	Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering (GlobeNewswire) -20.87%

Jyong Biotech Ltd. operates as a holding company, which engages in the development of biotechnology products. It offers plant-derived drugs that focus on the treatment of urinary system diseases. The company was founded by Fu Feng Kuo in July 2002 and is headquartered in New Taipei, Taiwan.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MENS

Jyong Biotech Ltd

Upgrade your FINVIZ experience